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ABSTRACT 
 
 
 
Human islet amyloid polypeptide (hIAPP) is secreted in the β-cells of the pancreas, 
which also secretes insulin. In type 2 diabetes mellitus, hIAPP undergoes self-aggregation, 
forming fibrils. This self-aggregation is cytotoxic and is thought to be linked to type 2 diabetes 
mellitus by causing β-cell membrane destruction. The N-terminus of hIAPP (1-19) contains a 
binding site (residues 14-18) for self-aggregation. Aggregation is thought to be mediated by pi-
stacking interactions between phenylalanine residues of hIAPP. In this study, the hIAPP 1-19 
sequence was modified by replacing phenylalanine with alanine and naphthylalanine, to study if 
the modification of the aromatic side chain alters aggregation and membrane destructive activity. 
The activity of the modified hIAPP sequences was tested against differently charged lipids, using 
a fluorescent dye leakage assay. Both modified hIAPP 1-19 sequences were found to be less 
active when compared to the original hIAPP 1-19 sequence. This might be due to lack of 
aromatic pi-stacking interactions at the 15th position or due to inappropriate structural 
conformation of the naphthylalanine analog. 
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1. INTRODUCTION 
 
1.1 Amyloid Proteins 
  The study of proteins is a constantly evolving field posing innumerable challenges and 
offering a great scope for future exploration. Researchers have deciphered a lot of links between 
different proteins and diseases, yet a large number of peptides and their significance in various 
diseases still remain unstudied. Amyloids are a class of proteins which are formed from amyloid 
precursor proteins. The amyloid proteins are known to form amyloid deposits, which have a 
common presence in the case of various diseases like Alzheimer’s disease, type II diabetes, and 
Parkinson’s disease. The plaques are found in different parts of the human body and are usually 
similar structurally, with slight distinctions depending upon the regions in which they are 
present. Therefore, the study of amyloid proteins carries a great importance due their 
involvement in various pathological occurrences.1  
 
1.2 Amyloid Deposits 
Amyloid deposits are formed due to misfolding of different amyloid proteins. The misfolding 
can occur either in the prefibrillar or the fibrillization assembly of the oligomers. The 
appearances of the amyloid deposits differ somewhat between disease states. These deposits are 
predominantly observed in the case of neurodegenerative disorders like Alzheimer’s disease, 
Down’s syndrome, and in pancreatic disorders like type 2 diabetes. During fibrillization of the 
amyloid proteins, different types of assembly states are observed, which exhibit a different 
spectrum of toxicities. Although the amyloid deposits contain proteins with different sequences, 
the basic structural characteristics of the deposits are similar.2  
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1.3 hIAPP  
Islet amyloid polypeptide (IAPP) is a 37-amino acid peptide which is secreted by the β-cells 
of the mammalian pancreas. Human islet amyloid polypeptide (hIAPP) is the human version of 
IAPP.  Insulin and hIAPP are co-secreted from the pancreas at varying ratios. 3 The role of 
hIAPP is to maintain the homeostasis of glucose in the body. Previous studies have indicated 
strong evidence for the presence of hIAPP aggregates in the pancreas of people suffering with 
type 2 diabetes. The in vitro mechanism of the hIAPP peptide aggregation has been extensively 
studied, but very little is known about the in vivo mechanism. The amyloid fibrils which are 
formed due to aggregation of the hIAPP peptide have been found to be cytotoxic to the β-cells of 
the pancreas, resulting in reduction of insulin production. The imbalance of the insulin level in 
the body affects the glucose metabolism in the body and subsequently leads to type 2 diabetes 
mellitus.4 
 
1.4 Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus is a rapidly growing disease which is affecting a population of 
approximately 140 million throughout the world. Type 1 diabetes mellitus is an autoimmune 
disorder which leads to apoptosis of the pancreatic β-cells, leading to a lack of insulin production 
in the body, which further leads to abnormal glucose levels in the body. In the case of type 2 
diabetes, a resistance is developed by the cells towards insulin, leading to a subsequent increase 
in the insulin levels followed by a decrease in the β-cell mass. This in turn leads to the abnormal 
regulation of glucose levels in the body. The insulin resistance of the cells triggers the islets to 
produce more insulin. As the insulin production is increased, the IAPP levels also increase 
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proportionally. Increased production of IAPP leads to the formation of amyloid fibrils which 
cause β-cell death, leading to type 2 diabetes. 5 
 
1.5 Amyloid Fibril Formation 
A substantial number of previous studies have proposed a common mechanism by which the 
hIAPP forms aggregates. The predicted mechanism involves a pathway leading to 
polymerization of the peptide, which is driven by nucleation.6 The mechanism is subdivided into 
two stages. In the first step, oligomeric seeds are formed, initiated by oligomeric nuclei.  This 
stage is called the lag phase, which initiates the monomeric nuclei to form soluble oligomers and 
subsequently leads to formation of a chain of oligomers, also called  protofibrils.7 The 
protofibrils combine together to form mature amyloid fibrils. Previous studies have indicated that 
the soluble oligomers exhibit higher cytotoxicity than the protofibrils and mature fibrils. Despite 
numerous attempts to understand the fibril formation, the actual mechanism is still not known.8 
Figure 1 shows the transformation of the peptide from monomers to amyloid deposits. 
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Figure 1: Formation of amyloid deposits-A and B depict the peptide in the monomeric form, 
gradually forming aggregates (C) leading to formation of protofibrils (D), transforming to 
mature fibrils (E) and finally forming amyloid deposits (F). 9 
 
1.6 Active sites of hIAPP 
Different fragments of the hIAPP peptide exhibit distinct roles in forming aggregates. A 
significant amount of research done on the 20-29 region revealed that it plays a major role in the 
fibrillization of hIAPP.  The 20-29 region is suspected to form anti-parallel conformations of 
beta sheets with other regions of the hIAPP, leading to aggregation. The 11-19 and 30-37 regions 
of hIAPP are thought to be interacting with the 20-29 region, causing anti-parallel conformations 
that almost look like an “S” shape. These monomers then interact to form the oligomers and 
fibrils. When compared to hIAPP, the 20 -29 region of rat IAPP (rIAPP) does not form the anti-
parallel beta sheet complex, which in turn restricts the formation of the pleated beta sheets and 
fibers.  This phenomenon in rats is thought to be due to the presence of proline residues which 
prevent the aggregation of the 20-29 region. 9 Most recently, the 1-19 region of the hIAPP is 
being widely studied due to its similarity in activity to that of the full length hIAPP despite its 
inability to form fibers by itself. This indicates that damaging membrane effects may be 
mediated by more than fiber formation. 10 
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1.7 hIAPP 1-19 
In recent studies, the hIAPP 1-19 region showed similar activity to that of the full length 
hIAPP in causing membrane disruption. The 1-19 sequence of hIAPP was found to show a stable 
conformation rendering an alpha-helical form, unlike the unstable beta-helical conformation of 
the full length hIAPP. Some studies indicate that the N-terminal region of the hIAPP 1-19 
sequence is involved in inducing the membrane disruption in addition to the 20-29 region.11 The 
membrane disruptive activity of the hIAPP 1-19 sequence was studied by comparing it with the 
rat version, which showed that the hIAPP 1-19 sequence showed a higher intensity of membrane 
disruption than that of the rIAPP 1-19. 10 Also, hIAPP 1-19 contains the 14-18 region which is 
thought to be a mediating site for the self-aggregation of the hIAPP sequence.1 Due to the smaller 
fragment size of the hIAPP 1-19 sequence and the similarity in activity to the full length 
sequence, it is easy to synthesize a relevant model to study hIAPP. The aromatic phenylalanine 
at the 15th position also allows study of aromatic pi-stacking interactions which are suspected to 
mediate the aggregation. Studies have also indicated that at higher concentrations, hIAPP 1-19 is 
actually more active than the full length hIAPP in causing membrane damage. 11 
 
1.8 Role of Aromatic Pi-stacking Interactions 
Recent studies have proposed that aromatic pi-stacking interactions play a role in the 
aggregation of the hIAPP peptide. The interactions between aromatic rings play a major role in 
the self-assembly of various biological molecules. These are nonbonding interactions which are 
found due to the alignment of the aromatic rings of different amino acid residues in the same 
parallel plane. This is a phenomenon in the self-assembly of proteins into their specific 
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conformations. These pi-stacking interactions play a major role in the self-assembly of the 
double helical structure of DNA, as well as forming a stable tertiary structure in the case of 
proteins. The favorable pi-stacking energy produced by these interactions was found to be 
entropy driven, causing the release of water molecules which are bound to the aromatic rings. 
Four possible pi-stacking interactions have been suggested, namely parallel displaced, T-shaped, 
parallel staggered and herringbone. Out of the four different models, the parallel displaced 
mechanism is highly prevalent among proteins. In the case of the parallel displaced pi-stacking 
mechanism, the aromatic residues are stacked in an anti-parallel direction upon each other in the 
same plane. In the case of hIAPP, this leads to the production of entropy-driven pi-stacking 
energy, which is suspected to cause the misfolding of the peptide and form aggregates. Figure 2 
shows the possible pi-stacking mechanisms that are commonly observed during the self assembly 
of various biological molecules.12 The hIAPP 1-19 fragment contains the aromatic phenylalanine 
at the 15th position, which might be studied for its role in aromatic pi-stacking interactions with 
other regions of hIAPP as well as insulin.   
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Figure 2: Aromatic pi-stacking mechanisms-(a) Parallel displaced mechanism, which is more 
prevalent in the case of proteins, (b) T-shaped mechanism, (c) Parallel staggered, and (d) 
Herringbone mechanism.12 
 
1.9 Membrane Disruption Mechanism of IAPP 
Several mechanisms have been suggested to explain the membrane disruptive activity of 
IAPP. The peptides are usually monomers at lower concentrations, and as the concentrations 
increase, they tend to assemble into an aggregate.13 At higher concentrations, the peptides are 
hypothesized to cause membrane disruption by three different mechanisms. The first mechanism 
is the barrel-stave mechanism, where the peptides aggregate resulting in the formation of pores 
within the membrane. The membrane disruption is predominantly caused by mature fibrils, and 
some studies indicate that the permeability of the membrane ends after complete fibrillization. 
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The second mechanism is the detergent-like mechanism, which involves rupturing the membrane 
by the peptide by forming high density micelles on the surface of the membrane. The third model 
is the toroidal wormhole, which works by lining the peptide within the lipid membrane, 
producing a curvature strain and subsequently leading to membrane disruption. The actual 
mechanism of the membrane disruption is still not understood completely. Based on the current 
evidence, it is suggested that all three types of membrane disruption mechanisms occur 
randomly.14  Figure 3 shows the different types of possible membrane disruption mechanisms. 
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 Figure 3: A schematic for the different mechanisms of membrane disruption. A- Peptide in the 
solution, B- Monomeric form of the peptide, C- Assembly of the peptide on the surface of the 
membrane, D- Barrel-stave mechanism, E- Toroidal wormhole mechanism and F- Detergent like 
action. 15 
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1.10 Solid Phase Peptide Synthesis 
 
Solid phase peptide synthesis (SPPS) is one of the widely used techniques for peptide 
synthesis. The method is well known for its option of choosing the protecting groups for the 
required peptide sequence and also offers flexibility in introducing synthetic amino acids. Both 
single and double coupling of the amino acids can be automatically performed by this method. 
The synthesis is initiated by a coupling and subsequent deprotection of amino acids in repeated 
cycles. The synthesizer is equipped with a reaction vessel which holds the resin required for the 
binding of the peptide. The resin is deprotected first, followed by the coupling of the carboxy 
terminus of the incoming amino acid, followed by deprotection of its N-terminus.  This process 
is continued for all of the amino acids required for the peptide sequence. In the final step, acetic 
anhydride can be used to cap the N-terminus of the peptide if desired. SPPS is classified into two 
forms, based on the protecting groups of the amino acids. The first form is the Fmoc form, which 
is currently in wide usage. A 20% v/v piperidine solution in N, N-dimethylformamide (DMF) is 
utilized for removing the fluorenyl oxymethyl carbonyl (Fmoc) protecting group of the amino 
acid. The second form is the one containing the t-butyl oxy carbonyl (Boc) deprotecting group. 
This method requires usage of hydrofluoric acid for final cleavage, which is considered 
hazardous. Although the Fmoc method is most commonly used for its simplicity and lesser risk, 
the Boc method has some advantages over the Fmoc method as it can be used for more complex 
processes. Also, when compared to Boc, the deprotection of the Fmoc group is more time-
consuming, because of the anionic nitrogen which is released as the end product of the 
synthesis.16 
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2. RESEARCH GOAL 
 
Type 2 diabetes mellitus is a major disease which affects a vast population around the 
world. A lot of investigation is underway to understand the pathology and to design a cure for the 
rapidly spreading epidemic. A common marker in all the cases of type 2 diabetic patients is the 
presence of human islet amyloid polypeptide (hIAPP) aggregates in the pancreas. The hIAPP 
aggregates are found to be cytotoxic to the pancreatic β-cells causing type 2 diabetes.The hIAPP 
protein is a 37 amino acid sequence, and various fragments of this peptide show different 
activities with regard to the amyloid fibril formation, which is believed to be the major driving 
force for cytotoxicity. Different theories have been proposed and new ones are being explored to 
understand the aggregation mechanism of the hIAPP peptide.  
    An aromatic pi-stacking interaction between various aromatic amino acid residues is one 
suspected reason for the aggregation of hIAPP. This hypothesis is not completely proven and is 
attracting a lot of research. Recent studies have indicated that the hIAPP 1-19 region is similar in 
activity to the full length hIAPP sequence. Due to a shorter amino acid sequence, the hIAPP 1-19 
fragment is economically feasible and easier to synthesize. Also it contains the 14-18 region of 
hIAPP which is linked to the self-aggregation process of the peptide.  
 The goal of this research is to understand the role of aromatic pi-stacking interactions in 
the aggregation of the hIAPP 1-19 sequence. Since the sequence contains an aromatic 
phenylalanine residue at the 15th position, it seems important to study whether the phenylalanine 
is involved in any aromatic pi-stacking interactions that might contribute to membrane damage. 
By replacing the aromatic phenylalanine with alanine, it might be possible to see a reduced 
activity on the membrane due to lack of an aromatic moiety and therefore no pi-stacking 
12 
 
interactions. Also, by increasing the aromatic nature by replacing the alanine with a 1-
naphthylalanine, which has an extra aromatic ring relative to the phenylalanine, we may observe 
an increase in aromatic pi-stacking interactions and subsequently aggregation and membrane 
damage. The activities of the modified hIAPP 1-19 analogs can then be compared to that of the 
unmodified hIAPP 1-19 sequence and also to the full length sequence to yield reasonable 
conclusions. 
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3. EXPERIMENTAL PROCEDURES 
 
3.1 Synthesis of Modified hIAPP 1-19 Peptide Sequences 
The solid phase peptide synthesis (SPPS) technique was employed to make the desired 
peptides. The necessary amino acids were weighed accurately and transferred into their 
respective vials. A constant amount of 0.4 mmol O-benzotriazole-N, N, N’, N’-
tetramethyluronium hexafluorophosphate (HBTU), a coupling agent, was added to all the vials. 
Each vial thus contained 0.4 mmol of the amino acid and 0.4 mmol HBTU.  The amino acids 
required for the specific peptide were arranged in the PS3 peptide synthesizer, from C-terminus 
through N –terminus, and 0.1 mmol of 4-methylbenzylhydrylamine hydrochloride (MBHA) resin 
was added to the reaction vessel. N, N-dimethylformamide (DMF) was used as the primary 
solvent and 20% (v/v) piperidine solution in DMF was used as a deprotecting agent. The 
coupling process was activated by using a 0.4 M N, N-diisopropylethylamine in DMF.  The 
peptide synthesis was performed using standard Fmoc procedures. The peptide sequences 
synthesized are listed in Table 1. 
 
Table 1. The modified hIAPP 1-19 sequences that were synthesized. 
Modified hIAPP sequences Amino acid sequence 
hIAPP 1-19  (Phe       Ala) KCNTATCATQRLANALVHS 
hIAPP 1-19 (Phe       Naphthylalanine) KCNTATCATQRLAN(Nal)LVHS 
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All of the ACS grade chemicals used in the synthesis were purchased from Fisher Scientific, and 
all of the amino acids used were purchased from Midwest Biotech Inc. Figure 4 shows the 
various amino acids that were replaced for the structural modification. 
A   
                                             B 
 
C 
 
 
 
Figure 4: Modified amino acids- (A) is phenylalanine, which is replaced by naphthylalanine (B) 
to increase the aromatic nature and replaced by alanine (C) to decrease the aromatic nature of the 
hIAPP 1-19 sequence. 17 
 
 
 
15 
 
3.2 Peptide Cleavage: 
After the completion of synthesis, the peptides were bound to the MBHA resin which 
was present in the reaction vessel. DMF was added into the reaction vessel to transfer the 
peptide-resin amalgam from the reaction vessel into a coarsely fritted glass funnel. The peptide-
resin mixture was rinsed using methylene chloride and dried under vacuum for 30 minutes. A 
solution comprising 0.5 mL water, 0.5 mL anisole, 10 ml trifluoroacetic acid, and a single crystal 
of phenol was prepared for the cleavage of the peptides. To cleave the peptides from the resin, 
the dried peptide-resin mixture was added to the solution prepared for cleavage and was 
constantly stirred for two hours at room temperature. The resin was separated from the mixture 
by filtration since it remained solid, whereas the peptide dissolved in the solution. The solution 
containing the peptide and solid resin was transferred into a coarsely fritted glass funnel, filtered 
under vacuum, and the filtrate was collected in a sidearm flask by constantly washing with TFA 
to collect the peptide completely.  
The peptide was precipitated from the filtrate by slowly adding 60 mL of cold diethyl 
ether with constant stirring. The solid peptide was separated from the solution by filtering it 
using a finely fritted glass funnel under vacuum for 25 minutes. The peptide was dissolved in a 
solution containing 70% acetonitrile/ H2O solution and an equal aliquot of distilled water. This 
solution was transferred into a lyophilization flask and frozen at -20o C for approximately 10 
hours. The flask containing the frozen solution was mounted on the lyophilizer overnight to 
completely dry out any trace of moisture from the peptide. The dry peptide was collected from 
the lyophilizer for further analysis. 
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3.3 Purification and Analysis of the Peptides 
The crude peptide which was obtained after lyophilization was collected and weighed 
accurately using an analytical balance. Reverse phase – high performance liquid chromatography 
(RP-HPLC) was employed to separate the impurities from the crude peptide and to determine the 
purity of the peptide. A Waters HPLC composed of a Waters 616 pump, a Waters 484 tunable 
absorbance UV detector, and a gradient controller was used for the preparative separation of the 
peptide from impurities. Trifluoroacetic acid (TFA) was used to dissolve the peptides and to 
facilitate injection into the HPLC. Solvent A was composed of 0.1% TFA in water and solvent B 
was made of 0.1% TFA in acetonitrile.  The column was equilibrated at 90% A: 10% B for 20 
minutes after which the peptide was injected. A Phenomemex Jupiter column (250 x 21.2 mm, 
C18, 10 µm and 300 Å) was used for the preparative separation process. After the injection of 
the peptide, the gradient was run, which increased the percentage of solvent B to 70% over a 
time of 2 hours. The pure peptide was manually collected into specific test tubes at a maximum 
wavelength of 280 nm. The test tubes supposedly containing the pure peptide were transferred 
into a lyophilization flask, frozen, and subsequently lyophilized to obtain the desired pure 
peptide. 
Analytical RP-HPLC was used to further determine the purity of the peptide obtained 
after preparative cleanup. A Waters HPLC containing two Waters 515 HPLC pumps, a Waters 
490E programmable multi-wavelength detector, a gradient controller, and a Phenomenex Jupiter 
analytical column (5 µm, C18, 250x4.6 mm and 300 Å) were used. Solvent A and solvent B 
were the same as those of the preparative run. A mass (1 mg) of the peptide was dissolved in 1 
mL TFA for injection. A gradient was run starting at 90% A and 10% B, which resulted in a 
solvent peak after approximately 2 minutes, followed by a single peptide peak after 30 minutes at 
17 
 
30% A and 70% B. For the hIAPP 1-19 sequence which was modified with alanine, the peptide 
peak was observed at a wavelength of 214 nm, and the hIAPP 1-19 peptide modified with 1- 
napthylalanine resulted in a peak at 254 nm. Peak integration revealed that the peptides were 
99% pure. The purity of the peptides was further confirmed by electrospray ionization-mass 
spectrometry, which showed that the peptides had the correct molecular weight. 
 
3.4 Fluorescent Dye Leakage Assay 
In order to study the activity of the peptides on model lipid membrane systems, a 
fluorescent dye leakage assay was utilized. The assay was designed based on a similar method 
developed by researchers at the University of Michigan. The initial stage of the assay involved 
preparation of lipid vesicles of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-
palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt) (POPG), and 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC): 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine] 
(sodium salt) (DOPS) (7:3). During the process, 5 mg of the lipid was dissolved in 2 mL of 
chloroform, followed by evaporation of chloroform using a low flow of nitrogen gas. A thin 
layer of lipid was formed on the walls of the test tube due to evaporation of the solvent, which 
was desiccated overnight under vacuum. The resulting lipid was dyed by adding 500 µL of 30 
mM carboxyfluorescein dye, dissolved in sodium phosphate buffer at pH 7.5.  The lipid and the 
dye solution were thoroughly mixed, followed by freeze-thaw cycles using liquid nitrogen. In 
order to prepare uniform vesicles for the assay, the solution was further processed 21 times using 
a mini-extruder manufactured by Avanti Polar Lipids, Inc. The dye-encapsulated vesicles were 
separated from the free dye by using a Sephadex G50 size exclusion column. The peptide 
solution was prepared by dissolving the purified peptide in DMSO at a concentration of 1 
18 
 
mg/mL, from which different aliquots were taken to analyze the activity. A solution of Triton X 
detergent was prepared for addition in the 100 % leakage control. Figure 5 shows the structures 
of the different kinds of lipid membranes used in the experiment. 
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A 
B 
   C 
 
D 
 
 
Figure 5: Structures of the lipid vesicles used in this study. (A) 1-palmitoyl-2-oleoyl-sn-glycero-
3-[phospho-rac-(1-glycerol)] (sodium salt)   (POPG) (B)1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), (C)1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), (D) 
1,2-dioleoyl-sn-glycero-3-[phospho-L-serine] (sodium salt) (DOPS). 18 
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Different aliquots of the peptide stock solution along with the required buffer solution 
and vesicles were mixed and analyzed using a Jasco FP-6300 spectrofluorometer. The excitation 
and emission wavelengths were set at 489 nm and 513 nm, respectively. The cuvette containing 
the required amount of the sample and vesicles was analyzed over the course of 300 s. A blank 
sample which contained DMSO, buffer solution, and vesicles was run initially, followed by a 
sample which contained the detergent as 100% leakage (positive control) since the detergent 
completely  breaks open the vesicles, releasing the dye. This process was repeated for each 
concentration of the peptide.  The data obtained from the fluorescence spectrum was analyzed 
using Microsoft Excel. A Bio-tek FLx-800 microplate fluorescence reader was also utilized to 
run some of the samples due to malfunction of the FT-spectrofluorometer. The concentrations of 
the samples to be analyzed were altered for the new spectrofluorometer, because the installed 96-
well plate reader could accommodate only 300 µL samples. However, the new method was 
advantageous as it facilitated running triplicates of the samples, providing consistency and 
reproducibility of the results. It also allowed monitoring over a longer time period. The average 
values of the triplicate results were compiled using Microsoft Excel. The percentage 
fluorescence is calculated using the formula: 
 
% Fluorescence =       Fluorescence of the sample – Control (DMSO only) 
                                    Fluorescence of the sample and detergent – Control (DMSO only) 
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4. RESULTS AND DISCUSSION 
 
4.1 Structural Modifications to hIAPP 1-19 Sequences 
 The hIAPP 1-19 sequence contains an aromatic phenylalanine residue at the 15th position, 
which was suspected to play a possible role in the aromatic pi-stacking which results in the 
formation of aggregates. The attempt was to confirm the role of aromatic pi-stacking in forming 
aggregates and causing membrane disruption by synthesizing two modified analogs of hIAPP 1-
19 peptide. In the case of the first analog, an attempt was made to reduce the aromatic nature of 
the peptide by replacing the phenylalanine with alanine. The second modification attempt was 
based on increasing the aromatic nature of the peptide by replacing the phenylalanine with 1-
naphthylalanine, which has an extra aromatic ring when compared to phenylalanine.  
 The purification of the first analog (15-ala) was unsuccessful the first time, because of 
improper solvent choice in dissolving the sample for the preparative HPLC. Initially, DMF was 
used to dissolve the peptide, which resulted in a gel-like solution, for unknown reasons. 
Subsequently, methanol was used to dissolve the peptide, which also did not properly dissolve 
the peptide, and not all of it could be recovered.  The peptide was synthesized for a second time, 
and TFA was used to dissolve the peptide for injection into the HPLC, and the purification was 
successful. The synthesis and purification of the second hIAPP 1-19 analog (15-naphthylala) was 
successful and did not require further attempts. The percentage yield of the first analog of hIAPP 
was only 50%, which is partially due to slowdown of the HPLC pump, which resulted in reduced 
flow rate. However, the purified peptide was further tested using mass spectrometry and 
analytical HPLC, which confirmed that the peptide was pure. The percentage yield of the second 
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analog of hIAPP was 85%, and the peptide was found to be pure based on mass spectrometry and 
analytical HPLC. 
 
4.2 Activity of the peptides on POPG 
The activity of the peptides was first tested on POPG lipid membranes. POPG is a 
negatively charged lipid which was supposed to show optimal activity with the hIAPP 1-19 
peptide and its analogs, due to the overall positive charges of the peptides. The hIAPP 1-19 
sequence, which was modified with alanine, showed an increase in dye leakage from the 
vesicles, as the concentration of the peptide was increased. An increase in the percentage 
fluorescence was observed as the concentration of the peptide was increased, which indicated an 
increase in the membrane disruptive activity of the peptide. There was a huge increase in the 
percentage fluorescence between the peptide concentrations 1µM and 3 µM. This sudden change 
in the activity indicates that the peptide might be active at higher concentrations, or that there 
might be a threshold amount of the particular peptide to be effective on the membrane. Figure 6 
shows the increasing activity of the hIAPP 1-19 peptide modified with alanine over time, with 
increase in the concentration of the peptide. At the maximum concentration tested (30 µM 
peptide), the percentage fluorescence was approximately 87%, which indicates a high membrane 
disruptive activity. 
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Figure 6: Percentage fluorescence due to dye leakage over time of the hIAPP 1-19 peptide 
modified with alanine on POPG. 
 
 The activity of the second analog of hIAPP 1-19, which was modified using 
naphthylalanine, was also tested on the POPG lipid. The naphthylalanine analog was expected to 
show increased activity relative to the non-aromatic analog of hIAPP 1-19, and unmodified 
hIAPP 1-19, because the increase in the aromaticity caused by naphthylalanine was supposed to 
induce the pi-stacking interactions which contribute to the increase in the membrane disruptive 
activity. The naphthylalanine containing analog was tested on POPG with increasing 
concentrations of the peptide, and concentration dependence was observed.  The activity of the 
naphylalanine modified hIAPP 1-19 analog was found to be similar to that of the analog 
modified using alanine. Figure 7 shows the activity of the naphthylalanine modified analog over 
time. The maximum percentage fluorescence observed at 30 µM was approximately 71%, which 
was slightly less than that of the alanine modified analog of hIAPP 1-19. The slight decrease in 
the percentage fluorescence of the naphthylalanine modified peptide was not clearly understood 
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but could be due to variability in the assay. A similar threshold concentration of 3 µM was 
observed. The activity of the naphthylalanine modified hIAPP 1-19 analog on POPG was found 
to be higher than that of the activity on DOPC: DOPS (7:3) membrane, which showed a 
threshold activity of approximately 25% leakage. 
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Figure 7:  Percentage fluorescence due to dye leakage over time of the hIAPP 1-19 peptide 
modified with naphthylalanine on POPG. 
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4.3 Activity of the peptides on POPC 
The peptides were further tested on POPC lipid, which is zwitterionic in nature. The 
peptides were expected to show lower activity on POPC than on POPG, due to its zwitterionic 
rather than negative nature, and the overall positive charges of the peptides. Both of the modified 
hIAPP 1-19 analogs were tested on POPC and showed less activity than on POPG as expected. 
Figure 8 shows the activity of the hIAPP 1-19 analog modified with alanine on POPC. At the 
highest concentration of 30 µM, the peptide exhibited approximately 25% of the fluorescence of 
the detergent treated vesicles, and an increasing pattern of leakage was observed with time at 
each concentration, especially the higher ones. 
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Figure 8:  Percentage fluorescence due to dye leakage over time of the hIAPP 1-19 peptide 
modified with alanine on POPC. 
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The activity of the hIAPP 1-19 analog modified with naphthylalanine showed similar 
activity on POPC. Figure 9 displays the activity of the hIAPP 1-19 analog modified with 
naphthylalanine on POPC. The maximum percentage fluorescence observed at 30 µM peptide 
concentration again was approximately 25%.  However, the activity of the peptide at lower 
concentrations was less than that of the hIAPP 1-19 analog modified with alanine, which was 
evident from the lower percentage fluorescence values at lower concentrations of the peptide. A 
similar trend was also observed in the activity of the peptides on POPG.  
 
0
5
10
15
20
25
30
0 50 100 150 200
%
 F
lu
o
re
s
c
e
n
c
e
Time (minutes)
hIAPP 1-19 modified with Naphthylalanine on POPC
1µM
3 µM
6 µM
10 µM
15 µM
30 µM
 
Figure 9:  Percentage fluorescence due to dye leakage over time of the hIAPP 1-19 peptide 
modified with naphthylalanine on POPC. 
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4.4 Activity of the peptides on DOPC: DOPS (7:3) 
The modified hIAPP 1-19 analogs were tested on vesicles composed of DOPC: DOPS 
(7:3) lipids. This mixture is generally considered to be closest to that of the β-cell membrane. 
DOPC is zwitterionic, and DOPS is negatively charged. The analog altered with alanine showed 
a maximum percentage fluorescence value of 13% at 30 µM. The activity of this analog was 
expected to be low due to its non-aromatic nature. The percentage fluorescence values increased 
consistently with increasing concentration of the peptide as expected. The overall activity of this 
peptide on DOPC: DOPS (7:3) was found to be less than that on both POPG and POPC.  In the 
case of POPG, this might be due to the more positive nature of DOPC: DOPS (7:3) compared to 
POPG, but the lower activity on this mixture than was observed on POPC was unexpected. Time 
dependence was not significantly observed during the assay. The pattern of the membrane 
disruptive activity of the hIAPP 1-19 modified with alanine is depicted in Figure 10. 
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Figure 10:  Percentage fluorescence due to dye leakage over time of the hIAPP 1-19 peptide 
modified with alanine on DOPC: DOPS (7:3). 
 
 The activity of the analog modified with naphthylalanine (Figure 11) displayed a similar 
trend as that of the non-aromatic analog on DOPC: DOPS (7:3). At equal concentrations, the 
activity of the hIAPP 1-19 analog modified with naphthylalanine was higher than that of the 
analog modified with alanine by roughly 3-8 fold. The percentage fluorescence value at the 
maximum concentration (30 µM) was approximately 30%, which was between the values of the 
activities recorded on POPC and POPG. However, at lower concentrations, the naphthylalanine 
analog showed less activity in this case than it did on the other two lipids. The reason for this 
poor activity at lower concentration may be due to a required threshold for interaction with the 
membrane. Indeed, a similar pattern of much lower activity at lower concentrations of the 
peptide was also evident in the case of its activity on POPG and POPC.  
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Figure 11:  Percentage fluorescence due to dye leakage over time of the hIAPP 1-19 peptide 
modified with naphthylalanine on DOPC: DOPS (7:3). 
 
4.5 Activity of full length hIAPP and hIAPP 1-19 on DOPC: DOPS (7:3) 
 Previous studies have indicated that the activity of the hIAPP 1-19 sequence is similar to 
that of the full length hIAPP 1-37 sequence.10 Studies carried out by Anitha Jayaprakash and 
Joshua Osborne in our laboratory have indicated that the activity of the full length hIAPP is 
actually slightly lower than the truncated hIAPP 1-19 sequence in this assay, at similar 
concentrations. Both the peptides displayed concentration dependence and slight time 
dependence. Figures 12 and 13 show the activities of the full length hIAPP and hIAPP 1-19, 
respectively, on DOPC: DOPS (7:3) membrane. The hIAPP 1-19 sequence showed the highest 
percentage leakage of about 80% at 30 µM, whereas the full length sequence showed a leakage 
of approximately 55% at 24.1 µM concentration. Also, at 6 µM concentration, the activity of the 
full length hIAPP sequence showed a percentage leakage of approximately 25% which is low 
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when compared to that of the unmodified hIAPP 1-19 sequence, which showed a percentage 
fluorescence of 40%. 
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Figure 12:  Percentage fluorescence due to dye leakage over time of the full length hIAPP 
peptide on DOPC: DOPS (7:3). 
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Figure 13:  Percentage fluorescence due to dye leakage over time of the unmodified hIAPP 1-19 
peptide on DOPC: DOPS (7:3). 
 
 The activities of both the modified hIAPP 1-19 analogs were found to be less than that of 
the unmodified hIAPP 1-19 sequence on the DOPC: DOPS (7:3) membrane. This might be due 
to improper folding of the peptides into a different conformation than the one required for 
causing membrane disruption. In the case of the 15-ala modified analog, the activity was 
expected to be low due to lack of aromatic phenylalanine residue. But this does not seem 
conclusive because the activity of the 15-naphthylala analog was also low, which was not 
expected. This indicates that disturbing the natural structure of the peptide might lead to 
unpredictable conformations. Also, it might be possible that the aromatic pi-stacking interactions 
do not play a significant role in the formation of aggregates in the case of hIAPP. 
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5. SUMMARY 
 
The activity of the hIAPP 1-19 region was found to be slightly higher than the activity of full 
length hIAPP 1-37 in causing disruption of lipid vesicles in the DOPC: DOPS (7:3) model 
membrane system. The mechanism of membrane disruption may be more than just fibril 
formation, since the truncated peptide lacks the 20-29 region commonly thought to primarily 
mediate fibrilization. The results indicate that the hIAPP 1-19 region can be used as a model in 
drug target studies, in place of the expensive and synthetically challenging full length hIAPP. 
The activity of both of the modified peptides was found to be lower than that of the original 
hIAPP 1-19 sequence on DOPC: DOPS (7:3), which is similar to the actual pancreatic cell 
membrane. This suggests that aromatic pi-stacking has no significant influence on the 
aggregation of the peptide or that the membrane disruption might be due to other mechanisms 
such as causing transient disorder of the acyl chains or head groups at the surface. It is also 
possible that pi-stacking is important, but that the naphthylalanine analog is unable to adapt to 
the appropriate structural conformation for aggregation. It might also be possible that a different 
geometrical isomer of naphthylanaine or a different aromatic moiety may adapt to the required 
structural conformation. Any deviation from the native sequence/ structure appears to be 
detrimental at this position. The aromatic pi-stacking interactions might exist at other aromatic 
residues, but not at the 15th position. 
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6. FUTURE WORK 
 
The role of insulin in the aggregation of hIAPP is widely being studied. Therefore it 
might be useful to study the activity of the hIAPP sequence along with insulin in the future. 
Testing the interactions between various structurally modified hIAPP sequences along with 
insulin analogs on various lipid membranes may help us understand the role of insulin in the 
aromatic pi-stacking interactions, which might subsequently lead to aggregation of hIAPP. Since 
insulin has been shown to inhibit fiber formation under some conditions, insulin-based inhibitors 
of the process may be developed. It is also important to focus on developing new assays to 
understand the extent of fibril formation. The use of POPG must be avoided as much as possible 
due to inconsistent results. The artificially negatively charged lipid leads to too much interaction 
with the peptides. As the activity on the DOPC: DOPS (7:3) membrane is similar to the activity 
on the actual pancreatic membrane, it can be considered more reliable when compared to POPG 
and POPC. This significantly reduces the length of the experiment and also helps to yield better 
results. Also, using molecular modeling may provide a good platform to predict the different 
structural conformations of hIAPP.  
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